Department of Immunohistocytology, Salah Azaïz Cancer Institute, Tunis, Tunisia.
Oncol Res Treat. 2017;40(4):167-172. doi: 10.1159/000458156. Epub 2017 Mar 15.
Several studies have outlined biological differences between female and male breast cancer (MBC) and concluded that MBC should be considered as an entirely separate disease. Whether FOXM1 has any indication for prognosis in MBC patients remains unknown. We sought to examine the expression levels of FOXM1 in MBC and to identify the relationship between FOXM1 expression and patient survival.
FOXM1 expression was evaluated in a total of 130 MBC specimens.
FOXM1 was overexpressed in 37% of the MBC samples. FOXM1 overexpression was significantly associated with tumor size (p = 0.045), histological grade (p = 0.048), lymph node metastasis (p = 0.012), Ki-67 proliferation index (p = 0.016), and molecular subtypes (p < 0.001). Multivariate analyses indicated that FOXM1 was an independent prognostic factor for overall survival in MBC patients (p < 0.001, hazard ratio = 0.69 (0.43-0.96)).
Overexpression of FOXM1 was associated with well-established markers of poor prognosis; thus FOXM1 may represent a potential novel prognostic marker for MBC.
多项研究概述了女性乳腺癌（MBC）和男性乳腺癌之间的生物学差异，并得出结论认为 MBC 应被视为一种完全独立的疾病。FOXM1 是否对 MBC 患者的预后有任何提示尚不清楚。我们试图检查 FOXM1 在 MBC 中的表达水平，并确定 FOXM1 表达与患者生存之间的关系。
总共评估了 130 例 MBC 标本中的 FOXM1 表达。
FOXM1 在 37%的 MBC 样本中过表达。FOXM1 过表达与肿瘤大小（p = 0.045）、组织学分级（p = 0.048）、淋巴结转移（p = 0.012）、Ki-67 增殖指数（p = 0.016）和分子亚型（p < 0.001）显著相关。多因素分析表明，FOXM1 是 MBC 患者总生存的独立预后因素（p < 0.001，风险比= 0.69（0.43-0.96））。
FOXM1 的过表达与预后不良的既定标志物相关；因此，FOXM1 可能代表 MBC 的一种潜在新型预后标志物。
